公开(公告)号：US20230146324A1

公开(公告)日：2023-05-11

申请号：US17683235

申请日：2022-02-28

Applicant: ModernaTX, Inc.

Inventor： John van Wicheren REYNDERS, III ,  Tirtha CHAKRABORTY ,  Stephen HOGE ,  Iain James MCFADYEN

IPC: C12P21/02 ,  A61K31/7088 ,  A61K38/02

CPC classification number: C12P21/02 ,  A61K31/7088 ,  A61K38/02 ,  C07K14/00

Abstract: The present disclosure provides multiparametric codon optimization methods to improve at least a property in a candidate nucleic acid sequence, for example the translation efficacy of a therapeutic mRNA.

公开(公告)号：US20220265774A1

公开(公告)日：2022-08-25

申请号：US17721583

申请日：2022-04-15

Applicant: ModernaTX, Inc.

Inventor： Joshua FREDERICK ,  Susannah HEWITT ,  Ailin BAI ,  Stephen HOGE ,  Vladimir PRESNYAK ,  Iain James MCFADYEN ,  Kerry BENENATO ,  Ellalahewage Sathyajith KUMARASINGHE

IPC: A61K38/20 ,  A61K9/51 ,  C07K14/54 ,  A61K31/7088 ,  A61K31/7115 ,  A61K48/00 ,  C12N15/62 ,  A61P35/00 ,  A61K9/00

Abstract: The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.

公开(公告)号：US20170362627A1

公开(公告)日：2017-12-21

申请号：US15525826

申请日：2015-11-04

Applicant: MODERNATX, INC.

Inventor： John van Wicheren REYNDERS, III ,  Tirtha CHAKRABORTY ,  Stephen HOGE ,  Iain James MCFADYEN

IPC: C12P21/02 ,  A61K38/02 ,  C07K14/00

CPC classification number: C12P21/02 ,  A61K38/02 ,  C07K14/00 ,  C07K2319/00

Abstract: The present disclosure provides multiparametric codon optimization methods to improve at least a property in a candidate nucleic acid sequence. Such parameters include improving nucleic acid stability (e.g., mRNA stability), increasing translation efficacy in the target tissue, reducing the number of truncated proteins expressed, improving the folding or prevent misfolding of the expressed proteins, reducing toxicity of the expressed products, reducing cell death caused by the expressed products, and increasing or decreasing protein aggregation. After such optimization, the resulting optimized nucleic acid sequence has at least one optimized property with respect to the candidate nucleic acid sequence.